|Spectral Diagnostics Inc.|
135-2 The West Mall
ON M9C 1C2
Canada - Map
Spectral Diagnostics Inc. engages in the development and commercialization of theranostic treatment for severe sepsis and septic shock in North America. Its products include Endotoxin Activity Assay for the identification of patients at risk of developing sepsis and certain proprietary biological reagents; and Toraymyxin, a therapeutic hemoperfusion device for the treatment of sepsis that removes endotoxin from the bloodstream. The company also develops, produces, and markets recombinant proteins, antibodies, and calibrators for use in research and development, as well as in products manufactured by other diagnostic companies. Spectral Diagnostics Inc. was founded in 1991 and is headquartered in Toronto, Canada.
|Dr. Paul M. Walker M.D., Ph.D., F.R.C.S.,
Chief Exec. Officer, Pres, Director and Member of Disclosure Committee
|Mr. Anthony Businskas CA,
Chief Financial Officer, Exec. VP, Sec. and Member of Disclosure Committee
|Ms. Debra-Anne M. Foster RN, B.Sc., CCRC,
VP of Clinical Devel.
|Dr. Gualtiero Guadagni ,
VP of Sales and Marketing
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in CAD.|